Hepatic Insufficiency/Liver Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major hepatic insufficiency/liver failure markets are expected to exhibit a CAGR of 3.79% during 2024-2034.
The hepatic insufficiency/liver failure market has been comprehensively analyzed in IMARC's new report titled "Hepatic Insufficiency/Liver Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatic insufficiency, often known as liver failure, is a potentially fatal condition defined by a significant deterioration in liver function. It is generally caused by liver abnormalities, which inhibit normal liver functioning in life-sustaining activities, making it difficult or impossible for the liver to operate. There are two different forms of liver failure. The first is acute liver failure, which develops rapidly due to situations such as the consumption of toxic compounds. The second form is chronic liver failure, which worsens liver function over a lengthy period of time, usually months to years. The early symptoms of this indication are identical to those of any other liver illness, including nausea, lack of appetite, exhaustion, and bowel troubles. However, as the condition progresses, other symptoms may arise. These symptoms usually involve fluid retention in the abdomen, often known as ascites, nausea that may escalate into vomiting containing blood due to blood vessel hemorrhage, itchiness, gallstones, jaundice, loss of musculature and body weight, and kidney damage. The patient could also experience mental disorientation as a result of the accumulation of toxicants in the blood. The first step in determining liver failure is to learn about the patient's medical history. The physician subsequently conducts a clinical exam on the patient. Following the examination, multiple blood tests are carried out to establish whether the liver is functioning normally, and a microscopic examination is performed to diagnose the exact type of liver failure. In many circumstances, the physician will request the patient undergo confirmatory tests such as a CT scan, endoscopy, MRI, and ultrasound to validate the liver failure.
The increasing incidences of autoimmune illnesses and viral infections, such as hepatitis, which can cause significant liver damage, are primarily driving the hepatic insufficiency/liver failure market. In addition to this, the rising prevalence of various associated risk factors, including excessive alcohol consumption, high doses of drugs like acetaminophen or paracetamol, advanced fatty liver, etc., are further bolstering the market growth. Moreover, the expanding geriatric population, who are more susceptible to numerous chronic ailments, such as liver disease, is also creating a positive outlook for the market. Besides this, several key players are making extensive investments in developing highly sensitive and rapid tests to detect liver diseases in specific populations, including pregnant women and HIV-positive patients. This, in turn, is further acting as a significant growth-inducing factor. Additionally, the increasing utilization of liver dialysis in the later stages of the disease for removing the toxins from the bloodstream, which the liver is unable to perform, is also propelling the global market. Apart from this, various biotechnological advancements, such as the introduction of the bioartificial liver, which utilizes regenerated cells to replace liver functions and is widely used for acute liver failure patients, are expected to drive the hepatic insufficiency/liver failure market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hepatic insufficiency/liver failure market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatic insufficiency/liver failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatic insufficiency/liver failure market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hepatic insufficiency/liver failure market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hepatic insufficiency/liver failure market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hepatic insufficiency/liver failure marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hepatic insufficiency/liver failure market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hepatic insufficiency/liver failure market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hepatic insufficiency/liver failure market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the hepatic insufficiency/liver failure patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hepatic insufficiency/liver failure?
What will be the growth rate of patients across the seven major markets?
Hepatic Insufficiency/Liver Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hepatic insufficiency/liver failure drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatic insufficiency/liver failure market?
The hepatic insufficiency/liver failure market has been comprehensively analyzed in IMARC's new report titled "Hepatic Insufficiency/Liver Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatic insufficiency, often known as liver failure, is a potentially fatal condition defined by a significant deterioration in liver function. It is generally caused by liver abnormalities, which inhibit normal liver functioning in life-sustaining activities, making it difficult or impossible for the liver to operate. There are two different forms of liver failure. The first is acute liver failure, which develops rapidly due to situations such as the consumption of toxic compounds. The second form is chronic liver failure, which worsens liver function over a lengthy period of time, usually months to years. The early symptoms of this indication are identical to those of any other liver illness, including nausea, lack of appetite, exhaustion, and bowel troubles. However, as the condition progresses, other symptoms may arise. These symptoms usually involve fluid retention in the abdomen, often known as ascites, nausea that may escalate into vomiting containing blood due to blood vessel hemorrhage, itchiness, gallstones, jaundice, loss of musculature and body weight, and kidney damage. The patient could also experience mental disorientation as a result of the accumulation of toxicants in the blood. The first step in determining liver failure is to learn about the patient's medical history. The physician subsequently conducts a clinical exam on the patient. Following the examination, multiple blood tests are carried out to establish whether the liver is functioning normally, and a microscopic examination is performed to diagnose the exact type of liver failure. In many circumstances, the physician will request the patient undergo confirmatory tests such as a CT scan, endoscopy, MRI, and ultrasound to validate the liver failure.
The increasing incidences of autoimmune illnesses and viral infections, such as hepatitis, which can cause significant liver damage, are primarily driving the hepatic insufficiency/liver failure market. In addition to this, the rising prevalence of various associated risk factors, including excessive alcohol consumption, high doses of drugs like acetaminophen or paracetamol, advanced fatty liver, etc., are further bolstering the market growth. Moreover, the expanding geriatric population, who are more susceptible to numerous chronic ailments, such as liver disease, is also creating a positive outlook for the market. Besides this, several key players are making extensive investments in developing highly sensitive and rapid tests to detect liver diseases in specific populations, including pregnant women and HIV-positive patients. This, in turn, is further acting as a significant growth-inducing factor. Additionally, the increasing utilization of liver dialysis in the later stages of the disease for removing the toxins from the bloodstream, which the liver is unable to perform, is also propelling the global market. Apart from this, various biotechnological advancements, such as the introduction of the bioartificial liver, which utilizes regenerated cells to replace liver functions and is widely used for acute liver failure patients, are expected to drive the hepatic insufficiency/liver failure market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hepatic insufficiency/liver failure market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatic insufficiency/liver failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatic insufficiency/liver failure market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hepatic insufficiency/liver failure market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hepatic insufficiency/liver failure market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hepatic insufficiency/liver failure marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hepatic insufficiency/liver failure market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hepatic insufficiency/liver failure market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hepatic insufficiency/liver failure market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the hepatic insufficiency/liver failure patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hepatic insufficiency/liver failure?
What will be the growth rate of patients across the seven major markets?
Hepatic Insufficiency/Liver Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hepatic insufficiency/liver failure drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatic insufficiency/liver failure market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEPATIC INSUFFICIENCY/LIVER FAILURE - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 HEPATIC INSUFFICIENCY/LIVER FAILURE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEPATIC INSUFFICIENCY/LIVER FAILURE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 HEPATIC INSUFFICIENCY/LIVER FAILURE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEPATIC INSUFFICIENCY/LIVER FAILURE - UNMET NEEDS
10 HEPATIC INSUFFICIENCY/LIVER FAILURE - KEY ENDPOINTS OF TREATMENT
11 HEPATIC INSUFFICIENCY/LIVER FAILURE - MARKETED PRODUCTS
11.1 List of Hepatic Insufficiency/Liver Failure Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 HEPATIC INSUFFICIENCY/LIVER FAILURE - PIPELINE DRUGS
12.1 List of Hepatic Insufficiency/Liver Failure - Pipeline Drugs Across the Top 7 Markets
12.1.1 E3112 - EA Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Soticlestat - Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 F 573 - EpiCept Corporation
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Mesenchymal Stem Cell Therapy (HepaStem) - Cellaion
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Resatorvid - Akaza Biopharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEPATIC INSUFFICIENCY/LIVER FAILURE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HEPATIC INSUFFICIENCY/LIVER FAILURE - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Hepatic Insufficiency/Liver Failure - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Hepatic Insufficiency/Liver Failure - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Hepatic Insufficiency/Liver Failure - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Hepatic Insufficiency/Liver Failure - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Hepatic Insufficiency/Liver Failure - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Hepatic Insufficiency/Liver Failure - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Hepatic Insufficiency/Liver Failure- Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Hepatic Insufficiency/Liver Failure - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Hepatic Insufficiency/Liver Failure - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
15 HEPATIC INSUFFICIENCY/LIVER FAILURE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 HEPATIC INSUFFICIENCY/LIVER FAILURE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEPATIC INSUFFICIENCY/LIVER FAILURE - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.3 Market Overview (2018-2023) and Forecast (2024-2034?)
4.4 Competitive Intelligence
5 HEPATIC INSUFFICIENCY/LIVER FAILURE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEPATIC INSUFFICIENCY/LIVER FAILURE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
8 HEPATIC INSUFFICIENCY/LIVER FAILURE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEPATIC INSUFFICIENCY/LIVER FAILURE - UNMET NEEDS
10 HEPATIC INSUFFICIENCY/LIVER FAILURE - KEY ENDPOINTS OF TREATMENT
11 HEPATIC INSUFFICIENCY/LIVER FAILURE - MARKETED PRODUCTS
11.1 List of Hepatic Insufficiency/Liver Failure Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 HEPATIC INSUFFICIENCY/LIVER FAILURE - PIPELINE DRUGS
12.1 List of Hepatic Insufficiency/Liver Failure - Pipeline Drugs Across the Top 7 Markets
12.1.1 E3112 - EA Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Soticlestat - Takeda
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 F 573 - EpiCept Corporation
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Mesenchymal Stem Cell Therapy (HepaStem) - Cellaion
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Resatorvid - Akaza Biopharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEPATIC INSUFFICIENCY/LIVER FAILURE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HEPATIC INSUFFICIENCY/LIVER FAILURE - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Hepatic Insufficiency/Liver Failure - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034?)
14.2.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034?)
14.3 Market Scenario - United States
14.3.1 Hepatic Insufficiency/Liver Failure - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034?)
14.3.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034?)
14.3.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Hepatic Insufficiency/Liver Failure - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034?)
14.4.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034?)
14.4.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Hepatic Insufficiency/Liver Failure - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034?)
14.5.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034?)
14.5.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Hepatic Insufficiency/Liver Failure - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034?)
14.6.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034?)
14.6.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Hepatic Insufficiency/Liver Failure - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034?)
14.7.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034?)
14.7.3 Hepatic Insufficiency/Liver Failure- Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Hepatic Insufficiency/Liver Failure - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034?)
14.8.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034?)
14.8.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Hepatic Insufficiency/Liver Failure - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034?)
14.9.2 Hepatic Insufficiency/Liver Failure - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034?)
14.9.3 Hepatic Insufficiency/Liver Failure - Access and Reimbursement Overview
15 HEPATIC INSUFFICIENCY/LIVER FAILURE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 HEPATIC INSUFFICIENCY/LIVER FAILURE MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
